オプションチェーンは、AMMOの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、AMMOの市場センチメントを評価します。.

AMMO (NASDAQ:POWW) 株価情報, オプションチェーン

AMMO

AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.

AMMO Inc

AMMO, Inc. - 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock

Baird analyst Richard Eastman maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Outperform and raises the price target from $305 to $315.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on Rockwell Automation, Raises Price Target to $315

WIIM

NGL Energy Partners shares are trading lower after the company reported Q3 financial results and missed its EPS estimate.

Rosenblatt analyst Hans Mosesmann maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $85 price target.

LSCC

Rosenblatt Maintains Buy on Lattice Semiconductor, Maintains $85 Price Target

Baird analyst Mike Polark maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Outperform and lowers the price target from $252 to $248.

INSP

Baird Maintains Outperform on Inspire Medical Systems, Lowers Price Target to $248

CRNT

Ceragon Networks shares are trading lower. The company reported Q4 financial results.

Biotech

General

LEXX

Lexaria Granted Two US Patents For The Use Of DehydraTECH In Epilepsy Treatment

Baird analyst David George maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Outperform and raises the price target from $75 to $80.

Baird Maintains Outperform on Comerica, Raises Price Target to $80

PSFE

Paysafe shares are trading lower after the company issued Q4 and FY24 revenue guidance below estimates.

Needham analyst Quinn Bolton maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $66 to $57.

Needham Maintains Buy on ON Semiconductor, Lowers Price Target to $57

Baird analyst Timothy Wojs maintains Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) with a Outperform and lowers the price target from $196 to $192.

Baird Maintains Outperform on Simpson Manufacturing Co, Lowers Price Target to $192

On Tuesday, Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted a fourth-quarter adjusted EPS loss of $(2.16), down from $(0.11) a year ago, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">in line with the consensus</a> and including <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" rel="noreferrer noopener">incremental investments in Stars</a>.
The company reported revenues of $29.19 billion, up 13.5% year-over-year from $25.73 billion, beating the&nbsp;consensus of $28.84 billion, primarily driven by higher per-member Medicare premiums and Medicare Advantage and state-based <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43618108/humana-reports-fourth-quarter-2024-financial-results-provides-full-year-2025-financial-guidance" rel="noreferrer noopener">contracts membership growth</a>, offset by a decline in stand-alone PDP membership, and a decline in membership in the group commercial medical business as a result of the company&#8217;s decision to exit the business.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
Humana&nbsp;ended the fourth quarter with 16.35 million in total medical membership, compared to 16.86 million a year ago. Individual Medicare Advantage membership&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/5334c95b-ebc7-41d7-bc1b-2c2a325606dd" rel="noreferrer noopener">reached</a> 5.66 million, up from 5.67 million a year ago.
Humana <a target="_blank" href="https://humana.gcs-web.com/static-files/fd6f79ca-bbaf-4401-b3e3-594ed340ec68" rel="noreferrer noopener">says</a> the insurance segment adjusted benefit ratio of 91.9%, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations.
Guidance: Humana expects 2025 GAAP sales of $126 billion-$128 billion versus the consensus of $119.41 billion.
Sales guidance includes Insurance segment sales of $121 billion—$123 billion and CenterWell segment sales of $20.5 billion—$21.5 billion.
The insurer expects individual Medicare Advantage annual membership decline of approximately 550,000, or approximately 10%, from 2024, inclusive of the company&#8217;s decision to exit certain unprofitable plans and counties, with group Medicare Advantage to remain relatively flat and Medicare stand-alone PDP growth of approximately 200,000.
Humana reaffirms the 2025 adjusted EPS outlook of $16.25 versus the consensus of $16.71.
For 2025, Humana expects its insurance segment&#8217;s benefit ratio guidance of approximately 90.1-90.5%.
In prepared remarks, Humana <a target="_blank" href="https://humana.gcs-web.com/static-files/fd6f79ca-bbaf-4401-b3e3-594ed340ec68" rel="noreferrer noopener">said</a>, &#8220;Our 2025 MA pricing strategy was focused on resetting pricing and membership to more accurately reflect the funding and medical cost trend environment, improving underlying margins.&#8221;
Price Action: HUM stock is up 3.07% at $274.99 during the premarket session on last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43604305/what-to-expect-when-biotech-giant-gilead-reports-q4-earnings-on-tuesday" target="_blank" rel="noreferrer noopener">What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Insurance Giant Humana's Q4 Earnings: 13% Revenue Growth, 2025 Profit Outlook Falls Below Street View

Advent Technologies Announces Launch Of The RESCUE Project; Advent's Approved Budget For The Initiative Is €2.16M

AREB

American Rebel Holdings shares are trading higher after the company announced it regained Nasdaq compliance.

DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) will release its fourth-quarter financial results, after the closing <a href="https://www.benzinga.com/quote/dash/earnings">bell, on Tuesday, Feb. 11, 2025.</a>
Analysts expect the San Francisco, California-based company to report quarterly earnings at 33 cents per share, down from 47 cents per share in the year-ago period. DoorDash projects quarterly revenue of $2.85 billion, compared to $2.3 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
DoorDash beat earnings expectations for the third quarter by more than 72%.
DoorDash shares fell 1.5% to close at $192.63 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/dash/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JMP Securities analyst Andrew Boone reiterated a Market Outperform rating with a price target of $200 on Feb. 6, 2025. This analyst has an accuracy rate of 82%.</li>
<li>UBS analyst Lloyd Walmsley maintained a Neutral rating and raised the price target from $182 to $200 on Feb. 3, 2025. This analyst has an accuracy rate of 86%.</li>
<li>Cantor Fitzgerald analyst Deepak Mathivanan reiterated an Overweight rating with a price target of $200 on Jan. 28, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Goldman Sachs analyst Eric Sheridan maintained a Neutral rating and raised the price target from $161 to $192 on Jan. 16, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Wells Fargo analyst Ken Gawrelski maintained an Equal-Weight rating and boosted the price target from $150 to $166 on Jan. 16, 2025. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying DASH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11033148/image-85-1024x603.png" alt="" class="wp-image-776021" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11033148/image-85-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11033148/image-85-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11033148/image-85-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11033148/image-85.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Markets

Trading Ideas

DASH

Top Wall Street Forecasters Revamp DoorDash Price Expectations Ahead Of Q4 Earnings

BHVN

Biohaven shares are trading higher after the company announced FDA acceptance and priority review of its new drug application for troriluzole.

Jefferies analyst Omar Nokta maintains Danaos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>) with a Buy and maintains $105 price target.

Jefferies Maintains Buy on Danaos, Maintains $105 Price Target

Baird analyst David Tarantino maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Neutral and raises the price target from $305 to $310.

Baird Maintains Neutral on McDonald's, Raises Price Target to $310

Editor&#8217;s Note: This story has been updated to correct Robin Li&#8217;s statement on AI investment at WGS.
Baidu&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) CEO Robin Li underscored the significance of ongoing investment&nbsp;in data centers and cloud&nbsp;infrastructure. This emphasis comes despite the cost-effectiveness of AI models like DeepSeek.
What Happened: At&nbsp;the World Government Summit in&nbsp;Dubai, Li highlighted the need for more investment to develop smarter models, reported Reuters. This statement comes amid the recognition of DeepSeek for creating language models that achieve performance comparable to top systems like OpenAI&#8217;s GPT while requiring significantly less computing power.
&#8220;The investment in cloud infrastructure is still very much required. In order to come up with models that are smarter than everyone else, you have to use more compute.&#8221;
Baidu was among the first Chinese companies to launch AI products after OpenAI released ChatGPT in late 2022. However, its large language model, Ernie—which Baidu claims is on par with GPT-4—has struggled to witness widespread public adoption.
"But in China, because of the constraints of compute, we have to innovate to reduce the cost both on the inference side and the training side. And fortunately, we&#8217;ve seen significant progress in the past year or so," he said He also appeared to take a more flexible stance admitting that open-source methods could speed up AI adoption.
&#8220;You just don&#8217;t know when and where innovations come from,&#8221; he said.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43613038/openais-chatgpt-surpasses-elon-musks-x-and-yahoo-to-rank-sixth-most-visited-website-globally-sam-altman-says-still-a-long-way-to-go-to-run-down-google">OpenAI&#8217;s ChatGPT Surpasses Elon Musk&#8217;s X To Rank Sixth Most-Visited Website Globally — Sam Altman Says, &#8216;Still A Long Way To Go To Run Down Google&#8217;</a>
Why It Matters: Baidu is emerging as a <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43600309/google-faces-rising-ai-rivals-like-baidu-and-yandex-but-analyst-sees-search-and-ad-growth-holding-strong">significant rival in the AI sector</a>, posing a challenge to giants like Google (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>). The limited public adoption of its AI model, Earnie indicates a potential area of growth and investment.
In an internal memo to the staff on the company&#8217;s 25th anniversary in January, Li stated, "While there's been no ‘super app' so far, the penetration ratio of AI is not low and we'll keep seeing exponential growth in 2025,&#8221; <a href="https://www.scmp.com/tech/big-tech/article/3293178/baidu-founder-robin-li-predicts-exponential-boom-ai-apps-2025">reported</a> the South China Morning Post. As the company pushes for AI adoption in the industrial space, Li acknowledged the associated risks in the memo.
Earlier, in January, CNBC&#8217;s Jim Cramer speculated about <a href="https://www.benzinga.com/markets/equities/25/01/43375128/jim-cramer-wonders-if-baidu-could-be-next-after-alibabas-ai-model-outperforms-deepseek">Baidu being the next Chinese tech giant </a>to gain market attention. This speculation followed Alibaba&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) AI model outperforming DeepSeek in several benchmarks, leading to a surge in Alibaba&#8217;s shares.
Baidu stock price has surged over 10% in the past six months to close at $93.85 yesterday.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/startups/25/02/43599833/data-on-deepseek-may-be-somehow-weaponized-against-the-united-states-suze-orman-says-the-ai-app-faces-similar-fate-as-tiktok">Data On DeepSeek May &#8216;Be Somehow Weaponized Against The United States&#8217; &#8211; Suze Orman Says The AI App Faces Similar Fate As TikTok</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

BABA

BIDU

GOOG

GOOGL

DeepSeek's Success Just The Start, More AI Funding 'Still Very Much Required,' Says Baidu CEO: 'You Just Don't Know When And Where Innovations Come From' (CORRECTED)

HYPR

Hyperfine shares are trading lower after the company announced a $6 million registered direct offering.

GOLF

Acushnet Holdings shares are trading higher after the company announced it will join the S&P SmallCap 600 index.

Investigation Into AMMO's Accounting Piles On Financial Weakness

FBI firearm background checks fell to a five-year low in 2024

AMMO (POWW) announced it has entered into a definitive agreement to sell its ammunition manufacturing assets to Olin Winchester, a subsidiary of Ol...

AMMO to sell ammunition manufacturing assets to Olin Winchester for $75M

AMMO ( ($POWW) ) has issued an update. On January 20, 2025, AMMO, Inc. announced the sale of its ammunition manufacturing assets to Olin-Winchester...

AMMO Sells Ammunition Assets to Olin-Winchester

Lake Street analyst Mark Smith maintained a Buy rating on AMMO (POWW – Research Report) today and set a price target of $3.00. The company's shares...

Lake Street Sticks to Their Buy Rating for AMMO (POWW)

Ammo blasts higher on sale of ammunition manufacturing assets to Olin

Pre-earnings options volume in AMMO (POWW) is normal with calls leading puts 17:1. Implied volatility suggests the market is anticipating a move ne...

AMMO options imply 17.1% move in share price post-earnings

Roth MKM analyst Matt Koranda maintained a Hold rating on AMMO (POWW – Research Report) today and set a price target of $1.75. The company's shares...

Roth MKM Remains a Hold on AMMO (POWW)

Pre-earnings options volume in AMMO (POWW) is normal with calls leading puts 891:1. Implied volatility suggests the market is anticipating a move n...

AMMO options imply 15.3% move in share price post-earnings

AMMO ( ($POWW) ) has released a notification of late filing. AMMO, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the peri...

AMMO, Inc. Delays 10-Q Filing Amid Financial Review

AOUT

POWW

POWWP

SPWH

SSTI

SWBI

Legal

Press Releases

AMMO, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 29, 2024 Deadline to file Lead Plaintiff Motion

POWW Investors Have Opportunity to Lead AMMO, Inc. Securities Fraud Lawsuit with the Schall Law Firm

POWW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AMMO, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Comments

AMMO

AMMO (POWW) オプション

AMMO (NASDAQ:POWW) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル